CHIANGMAI, Thailand, Feb. 22, 2025 /PRNewswire/ -- Thailand's hospitality industry has reached a new milestone with Furama Hotel Chiang Mai, the first hotel in the country to deeply integrate smart technology into its operations. Powered by KEENON Robotics' advanced service robots, this transformation marks a significant leap in enhancing guest experiences and operational efficiency in the hotel sector.
The official launch ceremony on 20 February 2025, brought together industry leaders, government officials, including Former MP Suraphol Kietchaiyakorn, Advisor to the Minister of Tourism and Sports, and Mr. Wiraphong Ritrod, Deputy Governor of Chiang Mai Province. The event highlighted the role of KEENON's robotic solutions in streamlining hotel services, from autonomous delivery to smart cleaning.
Smart Technology Elevating Hospitality
Located in the heart of Chiang Mai, Furama Hotel Chiang Mai is the first in Thailand to integrate smart technology into its operations. With KEENON Robotics' solutions, the hotel enhances operation efficiency while maintaining personalized service. Key innovations include:
- Smart Delivery Solutions: KEENON's DINERBOT and BUTLERBOT series manage meal delivery, table bussing, room service, guest guidance, and more. The BUTLERBOT, equipped with an elevator interface, enables smooth cross-floor delivery with enclosed cabins for increased hygiene and privacy, ensuring timely service.
- Smart Cleaning Solutions: The KLEENBOT C30 ensures a hygienic and comfortable environment by maintaining public areas with precision. Offering a 3-in-1 waterless cleaning solution, it efficiently sweeps, dust mops, and vacuums while operating quietly, making it an invaluable asset to the hotel's cleaning operations.
- Heavy Load Delivery Solution: The KEENON S100, with its heavy-duty capacity of over 100 kg, handles bulky items such as hotel linens, luggage, and supplies. It streamlines both back-of-house logistics and guest-facing deliveries, ensuring uninterrupted, end-to-end delivery for a seamless guest experience.
Paving the Way for Smarter Hotel Operations
The integration of smart technology at Furama Chiang Mai underscores the growing role of automation in the hospitality sector. With the global service robot market projected to reach $90 billion by 2030, hotels are increasingly turning to automation to improve service and management, aligning with Thailand's digital transformation goals.
At the event, Mr. Wiraphong Ritrod, Deputy Governor of Chiang Mai Province, said, "Partnerships like this between technology innovators and the hospitality sector set a strong example of how we can move forward together, making our city an even more attractive destination for tourists and investors."
"We are thrilled to support this transition to smart hospitality," said Mr. Bin Wan, COO of KEENON Robotics. "Our solutions are designed to help optimize hotel operations while ensuring an elevated guest experience. This marks the beginning of a new era in smart hospitality."
Thailand's tourism and hospitality sector is a key driver of the country's economy, and the introduction of smart hotel technology is expected to further boost its competitiveness on the global stage. The integration of KEENON Robotics' solutions aligns with Thailand's broader goals of embracing digital transformation and sustainable tourism.
About KEENON Robotics
A global leader in commercial service robots and solutions, KEENON Robotics has been at the forefront of the advanced service robot market since 2010. Harnessing cutting-edge technologies in robotics and cloud computing, the company is trusted by businesses worldwide. KEENON Robotics is dedicated to creating value, fostering innovation, and contributing to industry growth across various sectors.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Celebrating Thailand's First Smart Hotel: A New Era in Hospitality with KEENON Robotics
Celebrating Thailand's First Smart Hotel: A New Era in Hospitality with KEENON Robotics
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
